Tuesday, May 4, 2010

New Data on NovaBay’s Aganocide compounds ( first-in-class anti-infectives) as presentations...

NovaBay Pharmaceuticals, Inc.  recently announced that, it is will be  presenting the latest public data on its Aganocide® compounds (see structures : a new class of broad-spectrum antimicrobials). 

Data will be presented during three poster sessions at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Fort Lauderdale, Florida. NovaBay's Aganocide compounds are first-in-class anti-infectives being developed for the treatment and prevention of antibiotic-resistant infections. NovaBay and Alcon, Inc., the world's leading eye care company, have a licensing and research collaboration agreement for the use of NovaBay's Aganocide compounds in the eye, ear and sinus, and for contact lens care.

The three presentations are :
1. Dichloro analog (AL-46383A) (see structure) as a Novel Topical Ophthalmic Agent, 2. In vitro evaluation of dichloro analog as an Antiviral Agent Against Adenovirus and HSV-1 and 3. topical dichloro analog,  Inhibits Adenovirus Replication in the Ocular Ad5/NZW Rabbit Replication Model.

NVC-422, or AL-46383A, is a stable compound based on the chemical structures of N-chlorotaurine (NCT) and N,N-dichlorotaurine, which are naturally occurring antimicrobial agents produced by the body's white blood cells to fight invasive pathogens.
Alcon is conducting a Phase 2 clinical trial of this compound for the treatment of viral conjunctivitis, a form of "pink eye". The randomized, placebo-controlled trial is enrolling approximately 250 patients at more than 30 medical centers in the United States and worldwide. It is designed to determine the safety and efficacy of NVC-422 or AL-46383A. 

Ref : http://www.novabaypharma.com/investors/release/apr_30_2010

No comments: